approval
saveRINVOQ (UPADACITINIB) — FDA approval
community read0 votes
Sponsor: ABBVIE. Form: TABLET, EXTENDED RELEASE. Route: ORAL
view source ↗Data sources
last refreshed 5mo ago
Found something off?
drug timeline · 8
- approvalRINVOQ (UPADACITINIB) — FDA approvalOct 10, 2025 · 360d ago
- approvalRINVOQ (UPADACITINIB) — FDA approvalAug 12, 2025 · 419d ago
- approvalRINVOQ (UPADACITINIB) — FDA approvalApr 28, 2025 · 525d ago
- approvalRINVOQ (UPADACITINIB) — FDA approvalApr 26, 2024 · 892d ago
- approvalRINVOQ (UPADACITINIB) — FDA approvalApr 26, 2024 · 892d ago
- approvalRINVOQ (UPADACITINIB) — FDA approvalNov 14, 2023 · 1056d ago
- approvalRINVOQ (UPADACITINIB) — FDA approvalJun 22, 2023 · 1201d ago
- approvalRINVOQ (UPADACITINIB) — FDA approvalMay 18, 2023 · 1236d ago
same company · ±60 days · 6
- approvalupadacitinib: RINVOQ LQ (UPADACITINIB) — FDA approvalMar 26, 2025
- approvalatogepant: QULIPTA (ATOGEPANT) — FDA approvalMar 21, 2025
- approvalupadacitinib tartrate ER: RINVOQ (UPADACITINIB) — FDA approvalApr 28, 2025
- approvaldivalproex sodium DR: DEPAKOTE (DIVALPROEX SODIUM) — FDA approvalMay 1, 2025
- approvaldivalproex sodium DR: DEPAKOTE ER (DIVALPROEX SODIUM) — FDA approvalMay 1, 2025
- approvaldivalproex sodium DR: DEPAKOTE (DIVALPROEX SODIUM) — FDA approvalMay 1, 2025
comments(0)
5-min edit window · permanent after that